[#item_full_content]ZAMUDIO, Spain–(BUSINESS WIRE)–Oncomatryx has acquired Tube Pharmaceuticals GmbH, the developer of the Cytolysin toxic payload. The multimillion €uros transaction is a strategic decision by Oncomatryx that will foster its leadership in the field of ADCs targeting the tumor microenvironment. It culminates a decade-long alliance between Oncomatryx and Tube that has already rendered clinical-stage ADCs targeting the Tumor Microenvironment. Oncomatryx’s pioneering drug OMTX705, which incorporates